Exjade(deferasirox)
Deferasirox, Exjade, Jadenu (deferasirox) is a small molecule pharmaceutical. Deferasirox was first approved as Exjade on 2005-11-02. It is used to treat iron overload in the USA. It has been approved in Europe to treat beta-thalassemia and iron overload.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Deferasirox, Exjade, Jadenu (discontinued: Deferasirox)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| deferasirox | ANDA | 2025-03-05 |
| deferasirox oral | ANDA | 2022-04-12 |
| deferasirox oral granules | ANDA | 2025-01-07 |
| deferasorox | ANDA | 2022-05-20 |
| exjade | New Drug Application | 2024-07-22 |
| jadenu | New Drug Application | 2024-07-18 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| iron overload | — | D019190 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Deferasirox, Jadenu, Novartis Pharms Corp | |||
| 9283209 | 2034-11-21 | DS, DP | |
HCPCS
No data
Clinical
Clinical Trials
106 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Iron overload | D019190 | — | — | 2 | 17 | 7 | 12 | 3 | 39 |
| Thalassemia | D013789 | EFO_1001996 | D56 | 1 | 9 | 4 | 8 | — | 22 |
| Myelodysplastic syndromes | D009190 | — | D46 | — | 11 | — | 6 | — | 17 |
| Preleukemia | D011289 | — | — | — | 9 | — | 6 | — | 15 |
| Beta-thalassemia | D017086 | Orphanet_848 | D56.1 | 1 | 6 | 3 | 5 | — | 15 |
| Syndrome | D013577 | — | — | — | 7 | — | 6 | — | 13 |
| Hemochromatosis | D006432 | EFO_1000642 | E83.11 | 1 | 6 | 2 | 4 | 1 | 13 |
| Hemosiderosis | D006486 | — | — | 1 | 6 | 2 | 4 | 1 | 13 |
| Anemia | D000740 | EFO_0004272 | D64.9 | — | 5 | 1 | 4 | 1 | 11 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | 3 | 2 | 1 | — | 6 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Porphyria cutanea tarda | D017119 | — | E80.1 | — | — | 1 | — | — | 1 |
| Erythropoietic porphyria | D017092 | — | — | — | — | 1 | — | — | 1 |
| Porphyrias | D011164 | EFO_0000665 | — | — | — | 1 | — | — | 1 |
| Hepatic porphyrias | D017094 | — | — | — | — | 1 | — | — | 1 |
| Primary myelofibrosis | D055728 | — | D47.4 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mucormycosis | D009091 | EFO_0007380 | B46.5 | — | 1 | — | — | — | 1 |
| Zygomycosis | D020096 | — | B46 | — | 1 | — | — | — | 1 |
| Hemolytic anemia | D000743 | — | D55-D59 | — | 1 | — | — | — | 1 |
| Fanconi anemia | D005199 | Orphanet_84 | D61.03 | — | 1 | — | — | — | 1 |
| Fanconi syndrome | D005198 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Deferasirox |
| INN | deferasirox |
| Description | Deferasirox is a member of the class of triazoles, deferasirox is 1,2,4-triazole substituted by a 4-carboxyphenyl group at position 1 and by 2-hydroxyphenyl groups at positions 3 and 5. An orally active iron chelator, it is used to manage chronic iron overload in patients receiving long-term blood transfusions. It has a role as an iron chelator. It is a member of triazoles, a monocarboxylic acid, a member of benzoic acids and a member of phenols. It is functionally related to a 2,2'-(1-phenyl-1H-1,2,4-triazole-3,5-diyl)diphenol. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 201530-41-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL550348 |
| ChEBI ID | 49005 |
| PubChem CID | 214348 |
| DrugBank | DB01609 |
| UNII ID | V8G4MOF2V9 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Exjade – Novartis
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,074 documents
View more details
Safety
Black-box Warning
Black-box warning for: Deferasirox, Deferasirox oral, Deferasirox oral granules, Deferasorox, Exjade, Jadenu
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
30,920 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use